

a new core area and strategic source for the innovation and development of cutting-edge medicine in Chengdu, and will endeavor to become a world-class landmark park for the new health economy, concentrating on the new business model incorporating cross-border integration of smart health, precision medicine, and cosmetic medicine. It was begun in late 2018 when some institutions cooperated with Sichuan University to build a cutting-edge medical center like the Chengdu Advanced Medical Sciences Center in the city.

Technology-driven: Focusing on innovation

Moreover, the Chengdu Advanced Medical Sciences Center (AMSC) keeps its focus on the latest basic medical research and clinical innovation driven by burgeoning technologies such as big data, artificial intelligence (AI), the Internet of Things, genomics, and more. With translational medicine as its innovation target and market application as its value orientation, the center has built a "community of shared interests, innovation, and development" to form a new model of business partners for school-site cooperation, in order to realize the integration and enhancement of innovation capabilities and the in situ metamorphosis of scientific and technological achievements.

So far, Chengdu Advanced Medical Sciences Center has initially introduced eight high-level R&D platform projects, including the Frontier Science Center for Disease-Related Molecular Network, the Medical Big Data Center, the Frontier Innovation Translational Platform for Dental Medicine Plus, the Leading Research Center for Stress Medicine, and the West China Rare Disease Research Institute. These platforms will drive the development of AMSC and help TLSP and phase II industry. It is home to 10 new drug R&D projects initiated by professors from Sichuan University, such as Biotech Solution and Discovery Co., Ltd., and 10 interactive cooperation projects, such as the collaboration between PerkinElmer and Farsoon Turing Additive Manufacturing Technology Co., Ltd. It has also introduced two top scientists at the academician level, 20 scientists recognized by the National Science Fund for Distinguished Young Scholars Program and the Changjiang Scholars Program, and over 100 professors and researchers. Thanks to the professional carrier space provided by the Chinese government and the high-level research centers and innovation teams introduced from Sichuan University, TLSP has successfully implemented the sequence of "innovation and R&D, incubation of results, and implementation of industrialization."

AMSC, as the innovation center of university and local government cooperation, integrates global high-quality resources through cooperation of government, industry, university, research, and application; realizes the transformation of technological achievements; and finally, radiates Chengdu and even Sichuan, which will help it become globally competitive in the future.

Who we are

Welcome to TLSP. Centering on the needs of businesses, our service team commits itself to establishing a public technology service platform for innovative drug R&D, building the Information Center of Tianfu Life Science Park, attracting talent, organizing various industrial exchange meetings and medical lectures, and assisting enterprises to apply for awards. Through these comprehensive activities, it is wedded to facilitating the development of business and biomedical industry.

Sponsored by



Produced by the Science/AAAS
Custom Publishing Office



Company profiles



Geneus Technologies, Ltd., founded in 2017, is a private company focusing on developing nanopore-based gene (DNA/RNA) sequencing devices and solutions. The key technologies include disruptive single-molecule sequencing chemistry, highly accurate and supersensitive current detecting circuits, large-scale integration of microelectromechanical systems-integrated circuits (MEMS-IC) chips, supercapacitor electrode, deep learning, etc.



MaxHealth Biotech, LLC, focuses on development and commercialization of safe and effective vaccines to serve global public health. By employing its cutting-edge technologies of antigen engineering and novel adjuvant formulations, MaxHealth has built a rich pipeline of prophylactic and therapeutic vaccines against major infectious diseases, allergies, and cancers; two lead candidates are expected to enter clinical development in 2020.



Chengdu FANXI Biopharma Co., Ltd., is a newly founded biomed company engaged in developing first-in-class or best-in-class innovative medicines, with an emphasis on the areas of oncology, viruses, and liver disease.



Cunde Therapeutics Co., Ltd., is an innovative biotechnology company specializing in manufacturing therapeutically valuable immune cells, and dedicated to developing cutting-edge cell-based therapies to combat medical conditions such as cancer and liver cirrhosis.



Xiling Lab Co., Ltd., a Chengdu-based biopharmaceutical company, was founded by Drs. Jinkun Huang and Dejian Xie in August 2016. The company has built a unique technology platform by utilizing modern homogeneous, heterogeneous, and biocatalysis technologies for the production of pharmaceutical intermediates, drug substances, and related specialty chemicals.



Farsoon Turing Additive Manufacturing Technology Co., Ltd., is a high-tech enterprise focusing on overall solutions for medical 3D printing. The company was founded in 2018, and is located in the Advanced Medical Sciences Center of the Biomedical Innovation Incubation Park in the Chengdu High-Tech Zone.